#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Trigeminal neuralgia Interstitial lung disease Oesophageal achalasia B precursor type acute leukaemia Peripheral primitive neuroectodermal tumour of soft tissue B-cell lymphoma Mucopolysaccharidosis III Immunodeficiency common variable Thrombocytopenia Familial amyotrophic lateral sclerosis Guillain-Barre syndrome Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Small intestine adenocarcinoma Fibrous dysplasia of bone Becker's muscular dystrophy More trials…

    Learn about Rare Diseases

    Stevens-Johnson syndrome – Life with Disease Acute respiratory distress syndrome – Basic Information Pituitary-dependent Cushing’s syndrome – Life with Disease Atypical teratoid/rhabdoid tumour of CNS Nodal marginal zone B-cell lymphoma – Treatment Marginal zone lymphoma – Diagnostics Adrenocortical carcinoma – Treatment Rhabdomyosarcoma recurrent – Diagnostics Mantle cell lymphoma refractory – Diagnostics Alternating hemiplegia of childhood More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSK5460025A Melphalan Hydrochloride Melphalan Elinzanetant Eprosartan Mesilate Ivabradine Triptorelin Acetate Mitazalimab Tegafur Gallium Citrate Ga-68 Nadroparin Calcium Lysine Acetate HUMAN COAGULATION FACTOR XIII Testosterone Undecanoate E.coli Polysaccharide Protein C Palbociclib Protamine Sulfate Soticlestat Cdr132L More therapies…

    Learn about Your Condition

    Hypertonic bladder Neuropathic arthropathy Short stature Oesophageal carcinoma Strongyloidiasis Ectopic pregnancy Essential thrombocythaemia Androgenetic alopecia Skin disorder Glomerulonephritis acute K-ras gene mutation Inclusion body myositis Papulopustular rosacea Tuberculosis Turner's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cutaneous lupus erythematosus

  • A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Chronic cutaneous lupus erythematosus
    • Cutaneous lupus erythematosus
    • Subacute cutaneous lupus erythematosus
    Belgium Bulgaria Czechia France Germany Greece +4

  • A Study of Anifrolumab for Patients with Cutaneous Lupus Erythematosus to Measure Changes in Skin and Blood Inflammation and Clinical Outcomes

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Cutaneous lupus erythematosus
    Investigated Drugs:
    • Anifrolumab
    Austria

  • Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Lenalidomide
    • Methotrexate
    France

  • Study of VENT-03 tablets in adults with active cutaneous lupus erythematosus with or without systemic lupus erythematosus

    Recruiting

    2 1
    Investigated Drugs:
    • VENT-03
    Bulgaria Czechia France Hungary Poland Spain

  • Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic cutaneous lupus erythematosus
    • Cutaneous lupus erythematosus
    • Subacute cutaneous lupus erythematosus
    Investigated Drugs:
    • Litifilimab
    Belgium Bulgaria France Germany Hungary Italy +5

  • Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

    Not yet recruiting

    3 1
    Belgium Bulgaria France Germany Greece Italy +4
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!